Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection. 2000

F Hoffmann, and G Notheis, and U Wintergerst, and J Eberle, and L Gürtler, and B H Belohradsky
Children's Hospital of the Ludwig Maximilians-University Munich, Germany. ida@KK-i.med.uni-muenchen.de

BACKGROUND In this retrospective study we compared the antiretroviral effect of regimens consisting of simultaneous administration of two protease inhibitors (PI) with at least one nucleoside reverse transcriptase inhibitor on plasma viral load (VL) and CD4 cell count in HIV-infected children intensively pretreated with nucleoside reverse transcriptase inhibitors and PIs. METHODS Eleven HIV-infected children were changed to antiretroviral combination regimens including two PIs and followed for a median time of 24 weeks. Group A comprised six patients who were given ritonavir + saquinavir (SQV) and Group B consists of five patients who were changed to nelfinavir + SQV. Patients were treated with these combinations with 2 PIs because of treatment failure (increasing viral load) of prior PI therapy or clinical signs of disease progression. METHODS Serial determinations of plasma viral load (Amplicor, Roche) and CD4 cells were performed every 4 to 8 weeks. The detection limit of the Amplicor-reverse transcriptase-PCR assay was 50 copies/ml (1.7 log10). RESULTS In Group A the median VL reduction was 1.1 log10 after 3 months and 1.4 log10 after 6 months. In Group B median VL decreased 0.1 and 0.2 log10 after 3 and 6 months. In both groups during the study period none of the patients reached undetectable VL. The relative changes of CD4 cells above baseline in Group A showed a median increase of 7% after 3 months and 23% after 6 months. In Group B after 3 months CD4 cells did not increase, and after 6 months the median relative increase was only 7%. Both combination therapies were well tolerated, not necessitating any drug interruption during study period. CONCLUSIONS In children with intensive prior antiretroviral treatment, a salvage therapy including two PIs demonstrated antiretroviral efficacy in some patients. In this study the reduction of the VL as well as the increase of CD4 cells was more pronounced with ritonavir + SQV than with nelfinavir + SQV. With both combinations complete suppression of HIV replication was not achieved. Therefore the long term effect of these combinations may be limited by the emergence of resistant HIV strains.

UI MeSH Term Description Entries
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

F Hoffmann, and G Notheis, and U Wintergerst, and J Eberle, and L Gürtler, and B H Belohradsky
August 1999, AIDS (London, England),
F Hoffmann, and G Notheis, and U Wintergerst, and J Eberle, and L Gürtler, and B H Belohradsky
January 2005, International journal of immunopathology and pharmacology,
F Hoffmann, and G Notheis, and U Wintergerst, and J Eberle, and L Gürtler, and B H Belohradsky
July 1999, AIDS (London, England),
F Hoffmann, and G Notheis, and U Wintergerst, and J Eberle, and L Gürtler, and B H Belohradsky
January 2001, HIV clinical trials,
F Hoffmann, and G Notheis, and U Wintergerst, and J Eberle, and L Gürtler, and B H Belohradsky
July 2003, AIDS (London, England),
F Hoffmann, and G Notheis, and U Wintergerst, and J Eberle, and L Gürtler, and B H Belohradsky
April 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
F Hoffmann, and G Notheis, and U Wintergerst, and J Eberle, and L Gürtler, and B H Belohradsky
October 2004, The Pediatric infectious disease journal,
F Hoffmann, and G Notheis, and U Wintergerst, and J Eberle, and L Gürtler, and B H Belohradsky
April 1998, The Journal of infectious diseases,
F Hoffmann, and G Notheis, and U Wintergerst, and J Eberle, and L Gürtler, and B H Belohradsky
September 1999, The Annals of pharmacotherapy,
F Hoffmann, and G Notheis, and U Wintergerst, and J Eberle, and L Gürtler, and B H Belohradsky
October 2000, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!